338 related articles for article (PubMed ID: 35849317)
1. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
5. Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.
Panettieri RA; Camargo CA; Cheema T; El Bayadi SG; Fiel S; Vila TM; Jain RG; Midwinter D; Thomashow B; Ludwig-Sengpiel A; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2022; 17():2043-2052. PubMed ID: 36072608
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
Bourdin A; Molinari N; Ferguson GT; Singh B; Siddiqui MK; Holmgren U; Ouwens M; Jenkins M; De Nigris E
Adv Ther; 2021 Jun; 38(6):3089-3112. PubMed ID: 33929661
[TBL] [Abstract][Full Text] [Related]
7. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
8. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
Tabberer M; Lomas DA; Birk R; Brealey N; Zhu CQ; Pascoe S; Locantore N; Lipson DA
Adv Ther; 2018 Jan; 35(1):56-71. PubMed ID: 29313286
[TBL] [Abstract][Full Text] [Related]
9. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).
Zheng J; Zhong N; Wang C; Huang Y; Chen P; Wang L; Hui F; Zhao L; Wang H; Luo L; Du X; Han Goh A; Lipson DA
COPD; 2018; 15(4):334-340. PubMed ID: 30265816
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
13. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
Lipson DA; Birk R; Brealey N; Zhu CQ
Adv Ther; 2020 Dec; 37(12):4894-4909. PubMed ID: 33011864
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
[TBL] [Abstract][Full Text] [Related]
16. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Bardsley S; Criner GJ; Halpin DMG; Han MK; Hanania NA; Hill D; Lange P; Lipson DA; Martinez FJ; Midwinter D; Siler TM; Singh D; Wise RA; van Zyl-Smit RN; Berkman N
Respir Med; 2022 Dec; 205():107040. PubMed ID: 36470149
[TBL] [Abstract][Full Text] [Related]
17. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
18. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
[TBL] [Abstract][Full Text] [Related]
19. Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
Stolz D; Hermansson E; Ouwens M; Singh B; Sharma A; Jackson D; Darken P; Marshall J; Bowen K; Müllerová H; Alcázar Navarrete B; Russell R; Han MK; Tansey-Dwyer D
Curr Med Res Opin; 2023 Oct; 39(10):1395-1405. PubMed ID: 37583267
[TBL] [Abstract][Full Text] [Related]
20. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
